Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
27,461
archived clinical trials in
Hematology

A Proposal to Test the Efficacy and Tolerability of Bortezomib in Pulmonary Chronic GVHD
A Phase 2 Proposal to Test the Efficacy and Tolerability of Bortezomib in Pulmonary Chronic GVHD
Status: Enrolling
Updated:  1/9/2018
Northwestern University
mi
from
Chicago, IL
A Proposal to Test the Efficacy and Tolerability of Bortezomib in Pulmonary Chronic GVHD
A Phase 2 Proposal to Test the Efficacy and Tolerability of Bortezomib in Pulmonary Chronic GVHD
Status: Enrolling
Updated: 1/9/2018
Northwestern University
mi
from
Chicago, IL
Click here to add this to my saved trials
A Phase 3, Multicenter, Randomized, Double-blind,Active-controlled, Parallel-group Trial With an Open-labelExtension Phase to Evaluate the Efficacy and Safety of OralE5501 Versus Eltrombopag, in Adults With Chronic ImmuneThrombocytopenia (Idiopathic Thrombocytopenic Purpura)
A Phase 3, Multicenter, Randomized, Double-blind, Active-controlled, Parallel-group Trial With an Open-label Extension Phase to Evaluate the Efficacy and Safety of Oral E5501 Versus Eltrombopag, in Adults With Chronic Immune Thrombocytopenia (Idiopathic Thrombocytopenic Purpura)
Status: Enrolling
Updated:  1/9/2018
Prairie Lakes Health Care System
mi
from
Watertown, SD
A Phase 3, Multicenter, Randomized, Double-blind,Active-controlled, Parallel-group Trial With an Open-labelExtension Phase to Evaluate the Efficacy and Safety of OralE5501 Versus Eltrombopag, in Adults With Chronic ImmuneThrombocytopenia (Idiopathic Thrombocytopenic Purpura)
A Phase 3, Multicenter, Randomized, Double-blind, Active-controlled, Parallel-group Trial With an Open-label Extension Phase to Evaluate the Efficacy and Safety of Oral E5501 Versus Eltrombopag, in Adults With Chronic Immune Thrombocytopenia (Idiopathic Thrombocytopenic Purpura)
Status: Enrolling
Updated: 1/9/2018
Prairie Lakes Health Care System
mi
from
Watertown, SD
Click here to add this to my saved trials
Effects of Bortezomib-Based Therapy on Cellular Immunity and Response to DC/Myeloma Fusion Vaccines in Vitro
Effect of Bortezomib (Velcade)-Based Therapy on Cellular Immunity and Response to DC/Myeloma Fusion Vaccines in Vitro
Status: Enrolling
Updated:  1/9/2018
Beth Israel Deaconess Medical Center
mi
from
Boston, MA
Effects of Bortezomib-Based Therapy on Cellular Immunity and Response to DC/Myeloma Fusion Vaccines in Vitro
Effect of Bortezomib (Velcade)-Based Therapy on Cellular Immunity and Response to DC/Myeloma Fusion Vaccines in Vitro
Status: Enrolling
Updated: 1/9/2018
Beth Israel Deaconess Medical Center
mi
from
Boston, MA
Click here to add this to my saved trials
Effects of Bortezomib-Based Therapy on Cellular Immunity and Response to DC/Myeloma Fusion Vaccines in Vitro
Effect of Bortezomib (Velcade)-Based Therapy on Cellular Immunity and Response to DC/Myeloma Fusion Vaccines in Vitro
Status: Enrolling
Updated:  1/9/2018
Dana-Farber Cancer Institute
mi
from
Boston, MA
Effects of Bortezomib-Based Therapy on Cellular Immunity and Response to DC/Myeloma Fusion Vaccines in Vitro
Effect of Bortezomib (Velcade)-Based Therapy on Cellular Immunity and Response to DC/Myeloma Fusion Vaccines in Vitro
Status: Enrolling
Updated: 1/9/2018
Dana-Farber Cancer Institute
mi
from
Boston, MA
Click here to add this to my saved trials
Donor Lymphocyte Infusion (DLI) of T-cells Genetically Modified With iCasp9 Suicide Gene
A Phase 1/2 Trial Evaluating Treatment of Emergent Graft Versus Host Disease (GvHD) With AP1903 After Planned Donor Infusions (DLIs) of T-cells Genetically Modified With the iCasp9 Suicide Gene in Patients With Hematologic Malignancies
Status: Enrolling
Updated:  1/9/2018
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Donor Lymphocyte Infusion (DLI) of T-cells Genetically Modified With iCasp9 Suicide Gene
A Phase 1/2 Trial Evaluating Treatment of Emergent Graft Versus Host Disease (GvHD) With AP1903 After Planned Donor Infusions (DLIs) of T-cells Genetically Modified With the iCasp9 Suicide Gene in Patients With Hematologic Malignancies
Status: Enrolling
Updated: 1/9/2018
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
SMAC Mimetic LCL161 Alone or With Cyclophosphamide in Treating Patients With Relapsed or Refractory Multiple Myeloma
Phase II Study of LCL161 Alone and in Combination With Cyclophosphamide in Patients With Relapsed or Refractory Multiple Myeloma
Status: Enrolling
Updated:  1/9/2018
Mayo Clinic Arizona
mi
from
Scottsdale, AZ
SMAC Mimetic LCL161 Alone or With Cyclophosphamide in Treating Patients With Relapsed or Refractory Multiple Myeloma
Phase II Study of LCL161 Alone and in Combination With Cyclophosphamide in Patients With Relapsed or Refractory Multiple Myeloma
Status: Enrolling
Updated: 1/9/2018
Mayo Clinic Arizona
mi
from
Scottsdale, AZ
Click here to add this to my saved trials
SMAC Mimetic LCL161 Alone or With Cyclophosphamide in Treating Patients With Relapsed or Refractory Multiple Myeloma
Phase II Study of LCL161 Alone and in Combination With Cyclophosphamide in Patients With Relapsed or Refractory Multiple Myeloma
Status: Enrolling
Updated:  1/9/2018
Mayo Clinic Florida
mi
from
Jacksonville, FL
SMAC Mimetic LCL161 Alone or With Cyclophosphamide in Treating Patients With Relapsed or Refractory Multiple Myeloma
Phase II Study of LCL161 Alone and in Combination With Cyclophosphamide in Patients With Relapsed or Refractory Multiple Myeloma
Status: Enrolling
Updated: 1/9/2018
Mayo Clinic Florida
mi
from
Jacksonville, FL
Click here to add this to my saved trials
SMAC Mimetic LCL161 Alone or With Cyclophosphamide in Treating Patients With Relapsed or Refractory Multiple Myeloma
Phase II Study of LCL161 Alone and in Combination With Cyclophosphamide in Patients With Relapsed or Refractory Multiple Myeloma
Status: Enrolling
Updated:  1/9/2018
The Mayo Clinic
mi
from
Rochester, MN
SMAC Mimetic LCL161 Alone or With Cyclophosphamide in Treating Patients With Relapsed or Refractory Multiple Myeloma
Phase II Study of LCL161 Alone and in Combination With Cyclophosphamide in Patients With Relapsed or Refractory Multiple Myeloma
Status: Enrolling
Updated: 1/9/2018
The Mayo Clinic
mi
from
Rochester, MN
Click here to add this to my saved trials
Study of Chimeric Fibril-Reactive Monoclonal Antibody 11-1F4 in Patients With AL Amyloidosis
Phase Ia/Ib Study of Chimeric Fibril-Reactive Monoclonal Antibody 11-1F4 in Patients With AL Amyloidosis
Status: Enrolling
Updated:  1/9/2018
Columbia University Medical Center
mi
from
New York, NY
Study of Chimeric Fibril-Reactive Monoclonal Antibody 11-1F4 in Patients With AL Amyloidosis
Phase Ia/Ib Study of Chimeric Fibril-Reactive Monoclonal Antibody 11-1F4 in Patients With AL Amyloidosis
Status: Enrolling
Updated: 1/9/2018
Columbia University Medical Center
mi
from
New York, NY
Click here to add this to my saved trials
An Extension of a Phase 1/2, Open Label, Dose Ranging Study of PRX-102 in Adult Fabry Patients
An Extension of Open Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Exploratory Efficacy Parameters of PRX-102 Administered by Intravenous Infusion Every 2 Weeks for 38 Weeks to Adult Fabry Patients
Status: Enrolling
Updated:  1/9/2018
Department of Human Genetics, Emory University School of Medicine
mi
from
Atlanta, GA
An Extension of a Phase 1/2, Open Label, Dose Ranging Study of PRX-102 in Adult Fabry Patients
An Extension of Open Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Exploratory Efficacy Parameters of PRX-102 Administered by Intravenous Infusion Every 2 Weeks for 38 Weeks to Adult Fabry Patients
Status: Enrolling
Updated: 1/9/2018
Department of Human Genetics, Emory University School of Medicine
mi
from
Atlanta, GA
Click here to add this to my saved trials
An Extension of a Phase 1/2, Open Label, Dose Ranging Study of PRX-102 in Adult Fabry Patients
An Extension of Open Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Exploratory Efficacy Parameters of PRX-102 Administered by Intravenous Infusion Every 2 Weeks for 38 Weeks to Adult Fabry Patients
Status: Enrolling
Updated:  1/9/2018
University of Iowa Health Clinics
mi
from
Iowa City, IA
An Extension of a Phase 1/2, Open Label, Dose Ranging Study of PRX-102 in Adult Fabry Patients
An Extension of Open Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Exploratory Efficacy Parameters of PRX-102 Administered by Intravenous Infusion Every 2 Weeks for 38 Weeks to Adult Fabry Patients
Status: Enrolling
Updated: 1/9/2018
University of Iowa Health Clinics
mi
from
Iowa City, IA
Click here to add this to my saved trials
An Extension of a Phase 1/2, Open Label, Dose Ranging Study of PRX-102 in Adult Fabry Patients
An Extension of Open Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Exploratory Efficacy Parameters of PRX-102 Administered by Intravenous Infusion Every 2 Weeks for 38 Weeks to Adult Fabry Patients
Status: Enrolling
Updated:  1/9/2018
University of Kansas Medical Center
mi
from
Kansas City, KA
An Extension of a Phase 1/2, Open Label, Dose Ranging Study of PRX-102 in Adult Fabry Patients
An Extension of Open Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Exploratory Efficacy Parameters of PRX-102 Administered by Intravenous Infusion Every 2 Weeks for 38 Weeks to Adult Fabry Patients
Status: Enrolling
Updated: 1/9/2018
University of Kansas Medical Center
mi
from
Kansas City, KA
Click here to add this to my saved trials
An Extension of a Phase 1/2, Open Label, Dose Ranging Study of PRX-102 in Adult Fabry Patients
An Extension of Open Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Exploratory Efficacy Parameters of PRX-102 Administered by Intravenous Infusion Every 2 Weeks for 38 Weeks to Adult Fabry Patients
Status: Enrolling
Updated:  1/9/2018
Johns Hopkins University School of Medicine
mi
from
Baltimore, MD
An Extension of a Phase 1/2, Open Label, Dose Ranging Study of PRX-102 in Adult Fabry Patients
An Extension of Open Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Exploratory Efficacy Parameters of PRX-102 Administered by Intravenous Infusion Every 2 Weeks for 38 Weeks to Adult Fabry Patients
Status: Enrolling
Updated: 1/9/2018
Johns Hopkins University School of Medicine
mi
from
Baltimore, MD
Click here to add this to my saved trials
An Extension of a Phase 1/2, Open Label, Dose Ranging Study of PRX-102 in Adult Fabry Patients
An Extension of Open Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Exploratory Efficacy Parameters of PRX-102 Administered by Intravenous Infusion Every 2 Weeks for 38 Weeks to Adult Fabry Patients
Status: Enrolling
Updated:  1/9/2018
Duke Univ Med Ctr
mi
from
Durham, NC
An Extension of a Phase 1/2, Open Label, Dose Ranging Study of PRX-102 in Adult Fabry Patients
An Extension of Open Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Exploratory Efficacy Parameters of PRX-102 Administered by Intravenous Infusion Every 2 Weeks for 38 Weeks to Adult Fabry Patients
Status: Enrolling
Updated: 1/9/2018
Duke Univ Med Ctr
mi
from
Durham, NC
Click here to add this to my saved trials
An Extension of a Phase 1/2, Open Label, Dose Ranging Study of PRX-102 in Adult Fabry Patients
An Extension of Open Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Exploratory Efficacy Parameters of PRX-102 Administered by Intravenous Infusion Every 2 Weeks for 38 Weeks to Adult Fabry Patients
Status: Enrolling
Updated:  1/9/2018
Research Baylor Institute of Metabolic Disease
mi
from
Dallas, TX
An Extension of a Phase 1/2, Open Label, Dose Ranging Study of PRX-102 in Adult Fabry Patients
An Extension of Open Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Exploratory Efficacy Parameters of PRX-102 Administered by Intravenous Infusion Every 2 Weeks for 38 Weeks to Adult Fabry Patients
Status: Enrolling
Updated: 1/9/2018
Research Baylor Institute of Metabolic Disease
mi
from
Dallas, TX
Click here to add this to my saved trials
An Extension of a Phase 1/2, Open Label, Dose Ranging Study of PRX-102 in Adult Fabry Patients
An Extension of Open Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Exploratory Efficacy Parameters of PRX-102 Administered by Intravenous Infusion Every 2 Weeks for 38 Weeks to Adult Fabry Patients
Status: Enrolling
Updated:  1/9/2018
O&O Alpan
mi
from
Fairfax, VA
An Extension of a Phase 1/2, Open Label, Dose Ranging Study of PRX-102 in Adult Fabry Patients
An Extension of Open Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Exploratory Efficacy Parameters of PRX-102 Administered by Intravenous Infusion Every 2 Weeks for 38 Weeks to Adult Fabry Patients
Status: Enrolling
Updated: 1/9/2018
O&O Alpan
mi
from
Fairfax, VA
Click here to add this to my saved trials
An Extension of a Phase 1/2, Open Label, Dose Ranging Study of PRX-102 in Adult Fabry Patients
An Extension of Open Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Exploratory Efficacy Parameters of PRX-102 Administered by Intravenous Infusion Every 2 Weeks for 38 Weeks to Adult Fabry Patients
Status: Enrolling
Updated:  1/9/2018
The Royal Melbourne Hospital
mi
from
Parkville,
An Extension of a Phase 1/2, Open Label, Dose Ranging Study of PRX-102 in Adult Fabry Patients
An Extension of Open Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Exploratory Efficacy Parameters of PRX-102 Administered by Intravenous Infusion Every 2 Weeks for 38 Weeks to Adult Fabry Patients
Status: Enrolling
Updated: 1/9/2018
The Royal Melbourne Hospital
mi
from
Parkville,
Click here to add this to my saved trials
Bortezomib and Bendamustine to Treat Relapsed/Refractory Myeloma
Phase II Trial of Bortezomib and Bendamustine in the Treatment of Relapsed/Refractory Myeloma
Status: Enrolling
Updated:  1/10/2018
New York University Langone Medical Center
mi
from
New York, NY
Bortezomib and Bendamustine to Treat Relapsed/Refractory Myeloma
Phase II Trial of Bortezomib and Bendamustine in the Treatment of Relapsed/Refractory Myeloma
Status: Enrolling
Updated: 1/10/2018
New York University Langone Medical Center
mi
from
New York, NY
Click here to add this to my saved trials
Sorafenib in Combination With Cytarabine and Clofarabine in Patients With Refractory or Relapsed Hematologic Malignancies
A Pilot Pharmacokinetic, Pharmacodynamic and Feasibility Study of Sorafenib in Combination With Cytarabine and Clofarabine in Patients With Refractory or Relapsed Hematologic Malignancies
Status: Enrolling
Updated:  1/10/2018
St. Jude Children's Research Hospital
mi
from
Memphis, TN
Sorafenib in Combination With Cytarabine and Clofarabine in Patients With Refractory or Relapsed Hematologic Malignancies
A Pilot Pharmacokinetic, Pharmacodynamic and Feasibility Study of Sorafenib in Combination With Cytarabine and Clofarabine in Patients With Refractory or Relapsed Hematologic Malignancies
Status: Enrolling
Updated: 1/10/2018
St. Jude Children's Research Hospital
mi
from
Memphis, TN
Click here to add this to my saved trials
Trial of Erlotinib in Patients With JAK-2 V617F Positive Polycythemia Vera
Phase II Trial of Erlotinib in Patients With JAK-2 V617F Positive Polycythemia Vera
Status: Enrolling
Updated:  1/10/2018
University of Oklahoma Health Sciences Center
mi
from
Oklahoma City, OK
Trial of Erlotinib in Patients With JAK-2 V617F Positive Polycythemia Vera
Phase II Trial of Erlotinib in Patients With JAK-2 V617F Positive Polycythemia Vera
Status: Enrolling
Updated: 1/10/2018
University of Oklahoma Health Sciences Center
mi
from
Oklahoma City, OK
Click here to add this to my saved trials
A Feasibility Study of Prophylactic White Blood Cell Transfusions
A Feasibility Study of White Blood Cell Transfusion for the Prevention of Infection in Acute Myelogenous Leukemia Patients Undergoing Front-Line or First Salvage Induction Therapy
Status: Enrolling
Updated:  1/10/2018
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
A Feasibility Study of Prophylactic White Blood Cell Transfusions
A Feasibility Study of White Blood Cell Transfusion for the Prevention of Infection in Acute Myelogenous Leukemia Patients Undergoing Front-Line or First Salvage Induction Therapy
Status: Enrolling
Updated: 1/10/2018
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
Combination Chemotherapy, Peripheral Stem Cell Transplantation, Biological Therapy, Pamidronate and Thalidomide in Treating Patients With Multiple Myeloma
Sequential High-Dose Melphalan and Busulfan/Cyclophosphamide Followed by Peripheral Blood Progenitor Cell Rescue, Interferon/Thalidomide and Pamidronate for Patients With Multiple Myeloma
Status: Enrolling
Updated:  1/10/2018
Banner Good Samaritan Medical Center
mi
from
Phoenix, AZ
Combination Chemotherapy, Peripheral Stem Cell Transplantation, Biological Therapy, Pamidronate and Thalidomide in Treating Patients With Multiple Myeloma
Sequential High-Dose Melphalan and Busulfan/Cyclophosphamide Followed by Peripheral Blood Progenitor Cell Rescue, Interferon/Thalidomide and Pamidronate for Patients With Multiple Myeloma
Status: Enrolling
Updated: 1/10/2018
Banner Good Samaritan Medical Center
mi
from
Phoenix, AZ
Click here to add this to my saved trials
Combination Chemotherapy, Peripheral Stem Cell Transplantation, Biological Therapy, Pamidronate and Thalidomide in Treating Patients With Multiple Myeloma
Sequential High-Dose Melphalan and Busulfan/Cyclophosphamide Followed by Peripheral Blood Progenitor Cell Rescue, Interferon/Thalidomide and Pamidronate for Patients With Multiple Myeloma
Status: Enrolling
Updated:  1/10/2018
City of Hope Comprehensive Cancer Center
mi
from
Duarte, CA
Combination Chemotherapy, Peripheral Stem Cell Transplantation, Biological Therapy, Pamidronate and Thalidomide in Treating Patients With Multiple Myeloma
Sequential High-Dose Melphalan and Busulfan/Cyclophosphamide Followed by Peripheral Blood Progenitor Cell Rescue, Interferon/Thalidomide and Pamidronate for Patients With Multiple Myeloma
Status: Enrolling
Updated: 1/10/2018
City of Hope Comprehensive Cancer Center
mi
from
Duarte, CA
Click here to add this to my saved trials
A Novel Sequential Treatment of Salvage and Reduced Intensity Conditioning (RIC) Chemotherapy for Allogeneic Stem-Cell Transplantation (SCT) for Primary Refractory and Relapsed Acute Myelogenous Leukemia (AML)
A Novel Sequential Treatment of Salvage and Reduced Intensity Conditioning RIC) Chemotherapy for Allogeneic Stem-Cell Transplantation (SCT)for Primary Refractory and Relapsed Acute Myelogenous Leukemia
Status: Enrolling
Updated:  1/12/2018
Weill-Cornell Medical College
mi
from
New York, NY
A Novel Sequential Treatment of Salvage and Reduced Intensity Conditioning (RIC) Chemotherapy for Allogeneic Stem-Cell Transplantation (SCT) for Primary Refractory and Relapsed Acute Myelogenous Leukemia (AML)
A Novel Sequential Treatment of Salvage and Reduced Intensity Conditioning RIC) Chemotherapy for Allogeneic Stem-Cell Transplantation (SCT)for Primary Refractory and Relapsed Acute Myelogenous Leukemia
Status: Enrolling
Updated: 1/12/2018
Weill-Cornell Medical College
mi
from
New York, NY
Click here to add this to my saved trials
An Observational Cohort Study of the Safety and Efficacy of Fibrinogen Concentrate, Human (FCH) in Subjects With Congenital Fibrinogen Deficiency
A Multicenter Study on the Retrospective Safety and Efficacy of Fibrinogen Concentrate (Human) (FCH) for Routine Prophylaxis, Treatment of Bleeding or Surgery in Subjects With Congenital Fibrinogen Deficiency With a Prospective Followup Component
Status: Enrolling
Updated:  1/12/2018
Clinical Research Facility
mi
from
Aurora, CO
An Observational Cohort Study of the Safety and Efficacy of Fibrinogen Concentrate, Human (FCH) in Subjects With Congenital Fibrinogen Deficiency
A Multicenter Study on the Retrospective Safety and Efficacy of Fibrinogen Concentrate (Human) (FCH) for Routine Prophylaxis, Treatment of Bleeding or Surgery in Subjects With Congenital Fibrinogen Deficiency With a Prospective Followup Component
Status: Enrolling
Updated: 1/12/2018
Clinical Research Facility
mi
from
Aurora, CO
Click here to add this to my saved trials
An Observational Cohort Study of the Safety and Efficacy of Fibrinogen Concentrate, Human (FCH) in Subjects With Congenital Fibrinogen Deficiency
A Multicenter Study on the Retrospective Safety and Efficacy of Fibrinogen Concentrate (Human) (FCH) for Routine Prophylaxis, Treatment of Bleeding or Surgery in Subjects With Congenital Fibrinogen Deficiency With a Prospective Followup Component
Status: Enrolling
Updated:  1/12/2018
Clinical Research Facility
mi
from
Las Vegas, NV
An Observational Cohort Study of the Safety and Efficacy of Fibrinogen Concentrate, Human (FCH) in Subjects With Congenital Fibrinogen Deficiency
A Multicenter Study on the Retrospective Safety and Efficacy of Fibrinogen Concentrate (Human) (FCH) for Routine Prophylaxis, Treatment of Bleeding or Surgery in Subjects With Congenital Fibrinogen Deficiency With a Prospective Followup Component
Status: Enrolling
Updated: 1/12/2018
Clinical Research Facility
mi
from
Las Vegas, NV
Click here to add this to my saved trials
An Observational Cohort Study of the Safety and Efficacy of Fibrinogen Concentrate, Human (FCH) in Subjects With Congenital Fibrinogen Deficiency
A Multicenter Study on the Retrospective Safety and Efficacy of Fibrinogen Concentrate (Human) (FCH) for Routine Prophylaxis, Treatment of Bleeding or Surgery in Subjects With Congenital Fibrinogen Deficiency With a Prospective Followup Component
Status: Enrolling
Updated:  1/12/2018
Clinical Research Facility
mi
from
Durham, NC
An Observational Cohort Study of the Safety and Efficacy of Fibrinogen Concentrate, Human (FCH) in Subjects With Congenital Fibrinogen Deficiency
A Multicenter Study on the Retrospective Safety and Efficacy of Fibrinogen Concentrate (Human) (FCH) for Routine Prophylaxis, Treatment of Bleeding or Surgery in Subjects With Congenital Fibrinogen Deficiency With a Prospective Followup Component
Status: Enrolling
Updated: 1/12/2018
Clinical Research Facility
mi
from
Durham, NC
Click here to add this to my saved trials
An Observational Cohort Study of the Safety and Efficacy of Fibrinogen Concentrate, Human (FCH) in Subjects With Congenital Fibrinogen Deficiency
A Multicenter Study on the Retrospective Safety and Efficacy of Fibrinogen Concentrate (Human) (FCH) for Routine Prophylaxis, Treatment of Bleeding or Surgery in Subjects With Congenital Fibrinogen Deficiency With a Prospective Followup Component
Status: Enrolling
Updated:  1/12/2018
mi
from
Calgary,
An Observational Cohort Study of the Safety and Efficacy of Fibrinogen Concentrate, Human (FCH) in Subjects With Congenital Fibrinogen Deficiency
A Multicenter Study on the Retrospective Safety and Efficacy of Fibrinogen Concentrate (Human) (FCH) for Routine Prophylaxis, Treatment of Bleeding or Surgery in Subjects With Congenital Fibrinogen Deficiency With a Prospective Followup Component
Status: Enrolling
Updated: 1/12/2018
mi
from
Calgary,
Click here to add this to my saved trials
Lenalidomide Maintenance Therapy After High Dose BEAM With or Without Rituximab
Phase I/II Study of Lenalidomide Maintenance Following BEAM (+/- Rituximab) for Chemo-Resistant or High Risk Non-Hodgkin's Lymphoma
Status: Enrolling
Updated:  1/13/2018
University of Kansas Hospital - Westwood Cancer Center
mi
from
Westwood, KA
Lenalidomide Maintenance Therapy After High Dose BEAM With or Without Rituximab
Phase I/II Study of Lenalidomide Maintenance Following BEAM (+/- Rituximab) for Chemo-Resistant or High Risk Non-Hodgkin's Lymphoma
Status: Enrolling
Updated: 1/13/2018
University of Kansas Hospital - Westwood Cancer Center
mi
from
Westwood, KA
Click here to add this to my saved trials
Lenalidomide Maintenance Therapy After High Dose BEAM With or Without Rituximab
Phase I/II Study of Lenalidomide Maintenance Following BEAM (+/- Rituximab) for Chemo-Resistant or High Risk Non-Hodgkin's Lymphoma
Status: Enrolling
Updated:  1/13/2018
Univ of Nebraska Med Ctr
mi
from
Omaha, NE
Lenalidomide Maintenance Therapy After High Dose BEAM With or Without Rituximab
Phase I/II Study of Lenalidomide Maintenance Following BEAM (+/- Rituximab) for Chemo-Resistant or High Risk Non-Hodgkin's Lymphoma
Status: Enrolling
Updated: 1/13/2018
Univ of Nebraska Med Ctr
mi
from
Omaha, NE
Click here to add this to my saved trials
Lenalidomide Maintenance Therapy After High Dose BEAM With or Without Rituximab
Phase I/II Study of Lenalidomide Maintenance Following BEAM (+/- Rituximab) for Chemo-Resistant or High Risk Non-Hodgkin's Lymphoma
Status: Enrolling
Updated:  1/13/2018
Seidman Cancer Center at University Hospitals Case Medical Center, Case Comprehensive Cancer Center
mi
from
Cleveland, OH
Lenalidomide Maintenance Therapy After High Dose BEAM With or Without Rituximab
Phase I/II Study of Lenalidomide Maintenance Following BEAM (+/- Rituximab) for Chemo-Resistant or High Risk Non-Hodgkin's Lymphoma
Status: Enrolling
Updated: 1/13/2018
Seidman Cancer Center at University Hospitals Case Medical Center, Case Comprehensive Cancer Center
mi
from
Cleveland, OH
Click here to add this to my saved trials
Colony-Stimulating Factors to Relieve Neutropenia in Patients With Recurrent Non-Hodgkin's Lymphoma
A Randomized, Multicenter, Open-Label Study of Single Dose Filgrastim-SD/01 Versus Daily Filgrastim Following ESHAP Chemotherapy for Non-Hodgkin's Lymphoma
Status: Enrolling
Updated:  1/13/2018
Jonsson Comprehensive Cancer Center at UCLA
mi
from
Los Angeles, CA
Colony-Stimulating Factors to Relieve Neutropenia in Patients With Recurrent Non-Hodgkin's Lymphoma
A Randomized, Multicenter, Open-Label Study of Single Dose Filgrastim-SD/01 Versus Daily Filgrastim Following ESHAP Chemotherapy for Non-Hodgkin's Lymphoma
Status: Enrolling
Updated: 1/13/2018
Jonsson Comprehensive Cancer Center at UCLA
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Colony-Stimulating Factors to Relieve Neutropenia in Patients With Recurrent Non-Hodgkin's Lymphoma
A Randomized, Multicenter, Open-Label Study of Single Dose Filgrastim-SD/01 Versus Daily Filgrastim Following ESHAP Chemotherapy for Non-Hodgkin's Lymphoma
Status: Enrolling
Updated:  1/13/2018
Univ of Nebraska Med Ctr
mi
from
Omaha, NE
Colony-Stimulating Factors to Relieve Neutropenia in Patients With Recurrent Non-Hodgkin's Lymphoma
A Randomized, Multicenter, Open-Label Study of Single Dose Filgrastim-SD/01 Versus Daily Filgrastim Following ESHAP Chemotherapy for Non-Hodgkin's Lymphoma
Status: Enrolling
Updated: 1/13/2018
Univ of Nebraska Med Ctr
mi
from
Omaha, NE
Click here to add this to my saved trials
Colony-Stimulating Factors to Relieve Neutropenia in Patients With Recurrent Non-Hodgkin's Lymphoma
A Randomized, Multicenter, Open-Label Study of Single Dose Filgrastim-SD/01 Versus Daily Filgrastim Following ESHAP Chemotherapy for Non-Hodgkin's Lymphoma
Status: Enrolling
Updated:  1/13/2018
Ireland Cancer Center
mi
from
Cleveland, OH
Colony-Stimulating Factors to Relieve Neutropenia in Patients With Recurrent Non-Hodgkin's Lymphoma
A Randomized, Multicenter, Open-Label Study of Single Dose Filgrastim-SD/01 Versus Daily Filgrastim Following ESHAP Chemotherapy for Non-Hodgkin's Lymphoma
Status: Enrolling
Updated: 1/13/2018
Ireland Cancer Center
mi
from
Cleveland, OH
Click here to add this to my saved trials
Randomized Open-Label Study of INCB047986 in Subjects With Primary Myelodysplastic Syndrome (MDS)
A Randomized, Open-Label, 2-Stage Study of INCB047986 Administered Orally to Subjects With Primary Myelodysplastic Syndrome (MDS) Refractory to or Unlikely to Respond to Erythropoiesis-Stimulating Agents (ESAs)
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
mi
from
Highland, CA
Randomized Open-Label Study of INCB047986 in Subjects With Primary Myelodysplastic Syndrome (MDS)
A Randomized, Open-Label, 2-Stage Study of INCB047986 Administered Orally to Subjects With Primary Myelodysplastic Syndrome (MDS) Refractory to or Unlikely to Respond to Erythropoiesis-Stimulating Agents (ESAs)
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
mi
from
Highland, CA
Click here to add this to my saved trials
Randomized Open-Label Study of INCB047986 in Subjects With Primary Myelodysplastic Syndrome (MDS)
A Randomized, Open-Label, 2-Stage Study of INCB047986 Administered Orally to Subjects With Primary Myelodysplastic Syndrome (MDS) Refractory to or Unlikely to Respond to Erythropoiesis-Stimulating Agents (ESAs)
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
mi
from
Morristown, NJ
Randomized Open-Label Study of INCB047986 in Subjects With Primary Myelodysplastic Syndrome (MDS)
A Randomized, Open-Label, 2-Stage Study of INCB047986 Administered Orally to Subjects With Primary Myelodysplastic Syndrome (MDS) Refractory to or Unlikely to Respond to Erythropoiesis-Stimulating Agents (ESAs)
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
mi
from
Morristown, NJ
Click here to add this to my saved trials
Randomized Open-Label Study of INCB047986 in Subjects With Primary Myelodysplastic Syndrome (MDS)
A Randomized, Open-Label, 2-Stage Study of INCB047986 Administered Orally to Subjects With Primary Myelodysplastic Syndrome (MDS) Refractory to or Unlikely to Respond to Erythropoiesis-Stimulating Agents (ESAs)
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
mi
from
Somerville, NJ
Randomized Open-Label Study of INCB047986 in Subjects With Primary Myelodysplastic Syndrome (MDS)
A Randomized, Open-Label, 2-Stage Study of INCB047986 Administered Orally to Subjects With Primary Myelodysplastic Syndrome (MDS) Refractory to or Unlikely to Respond to Erythropoiesis-Stimulating Agents (ESAs)
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
mi
from
Somerville, NJ
Click here to add this to my saved trials
Randomized Open-Label Study of INCB047986 in Subjects With Primary Myelodysplastic Syndrome (MDS)
A Randomized, Open-Label, 2-Stage Study of INCB047986 Administered Orally to Subjects With Primary Myelodysplastic Syndrome (MDS) Refractory to or Unlikely to Respond to Erythropoiesis-Stimulating Agents (ESAs)
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
mi
from
Germantown, TN
Randomized Open-Label Study of INCB047986 in Subjects With Primary Myelodysplastic Syndrome (MDS)
A Randomized, Open-Label, 2-Stage Study of INCB047986 Administered Orally to Subjects With Primary Myelodysplastic Syndrome (MDS) Refractory to or Unlikely to Respond to Erythropoiesis-Stimulating Agents (ESAs)
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
mi
from
Germantown, TN
Click here to add this to my saved trials
Randomized Open-Label Study of INCB047986 in Subjects With Primary Myelodysplastic Syndrome (MDS)
A Randomized, Open-Label, 2-Stage Study of INCB047986 Administered Orally to Subjects With Primary Myelodysplastic Syndrome (MDS) Refractory to or Unlikely to Respond to Erythropoiesis-Stimulating Agents (ESAs)
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
mi
from
Indianapolis, IN
Randomized Open-Label Study of INCB047986 in Subjects With Primary Myelodysplastic Syndrome (MDS)
A Randomized, Open-Label, 2-Stage Study of INCB047986 Administered Orally to Subjects With Primary Myelodysplastic Syndrome (MDS) Refractory to or Unlikely to Respond to Erythropoiesis-Stimulating Agents (ESAs)
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Randomized Open-Label Study of INCB047986 in Subjects With Primary Myelodysplastic Syndrome (MDS)
A Randomized, Open-Label, 2-Stage Study of INCB047986 Administered Orally to Subjects With Primary Myelodysplastic Syndrome (MDS) Refractory to or Unlikely to Respond to Erythropoiesis-Stimulating Agents (ESAs)
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
mi
from
Houston, TX
Randomized Open-Label Study of INCB047986 in Subjects With Primary Myelodysplastic Syndrome (MDS)
A Randomized, Open-Label, 2-Stage Study of INCB047986 Administered Orally to Subjects With Primary Myelodysplastic Syndrome (MDS) Refractory to or Unlikely to Respond to Erythropoiesis-Stimulating Agents (ESAs)
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
mi
from
Houston, TX
Click here to add this to my saved trials
Randomized Open-Label Study of INCB047986 in Subjects With Primary Myelodysplastic Syndrome (MDS)
A Randomized, Open-Label, 2-Stage Study of INCB047986 Administered Orally to Subjects With Primary Myelodysplastic Syndrome (MDS) Refractory to or Unlikely to Respond to Erythropoiesis-Stimulating Agents (ESAs)
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
mi
from
Burlington, VT
Randomized Open-Label Study of INCB047986 in Subjects With Primary Myelodysplastic Syndrome (MDS)
A Randomized, Open-Label, 2-Stage Study of INCB047986 Administered Orally to Subjects With Primary Myelodysplastic Syndrome (MDS) Refractory to or Unlikely to Respond to Erythropoiesis-Stimulating Agents (ESAs)
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
mi
from
Burlington, VT
Click here to add this to my saved trials
A Study to Determine the Effect and Safety of an Oral Janus Kinase 2 (JAK2)-Inhibitor (Ruxolitinib; INBC018424) in Patients With Multiple Myeloma
A Phase 2, Two Stage, Open-label, Clinical Trial to Determine the Therapeutic Effect and Safety of an Oral JAK2-inhibitor (INCB018424) in Patients With Relapsed or Refractory Multiple Myeloma
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
mi
from
Highland, CA
A Study to Determine the Effect and Safety of an Oral Janus Kinase 2 (JAK2)-Inhibitor (Ruxolitinib; INBC018424) in Patients With Multiple Myeloma
A Phase 2, Two Stage, Open-label, Clinical Trial to Determine the Therapeutic Effect and Safety of an Oral JAK2-inhibitor (INCB018424) in Patients With Relapsed or Refractory Multiple Myeloma
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
mi
from
Highland, CA
Click here to add this to my saved trials
A Study to Determine the Effect and Safety of an Oral Janus Kinase 2 (JAK2)-Inhibitor (Ruxolitinib; INBC018424) in Patients With Multiple Myeloma
A Phase 2, Two Stage, Open-label, Clinical Trial to Determine the Therapeutic Effect and Safety of an Oral JAK2-inhibitor (INCB018424) in Patients With Relapsed or Refractory Multiple Myeloma
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
mi
from
Boynton Beach, FL
A Study to Determine the Effect and Safety of an Oral Janus Kinase 2 (JAK2)-Inhibitor (Ruxolitinib; INBC018424) in Patients With Multiple Myeloma
A Phase 2, Two Stage, Open-label, Clinical Trial to Determine the Therapeutic Effect and Safety of an Oral JAK2-inhibitor (INCB018424) in Patients With Relapsed or Refractory Multiple Myeloma
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
mi
from
Boynton Beach, FL
Click here to add this to my saved trials
A Study to Determine the Effect and Safety of an Oral Janus Kinase 2 (JAK2)-Inhibitor (Ruxolitinib; INBC018424) in Patients With Multiple Myeloma
A Phase 2, Two Stage, Open-label, Clinical Trial to Determine the Therapeutic Effect and Safety of an Oral JAK2-inhibitor (INCB018424) in Patients With Relapsed or Refractory Multiple Myeloma
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
mi
from
New York, NY
A Study to Determine the Effect and Safety of an Oral Janus Kinase 2 (JAK2)-Inhibitor (Ruxolitinib; INBC018424) in Patients With Multiple Myeloma
A Phase 2, Two Stage, Open-label, Clinical Trial to Determine the Therapeutic Effect and Safety of an Oral JAK2-inhibitor (INCB018424) in Patients With Relapsed or Refractory Multiple Myeloma
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
mi
from
New York, NY
Click here to add this to my saved trials
Vorinostat, Bortezomib, and Doxorubicin Hydrochloride Liposome in Treating Patients With Relapsed or Refractory Multiple Myeloma
A Phase 1 Dose Escalation Study of Bortezomib (Velcade®), Pegylated Liposomal Doxorubicin (Doxil®), and Vorinostat (Suberoylanilide Hydromaxic Acid, Saha, Zolinzatm) in Patients With Relapse/Refractory Multiple Myeloma
Status: Enrolling
Updated:  1/16/2018
Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill
mi
from
Chapel Hill, NC
Vorinostat, Bortezomib, and Doxorubicin Hydrochloride Liposome in Treating Patients With Relapsed or Refractory Multiple Myeloma
A Phase 1 Dose Escalation Study of Bortezomib (Velcade®), Pegylated Liposomal Doxorubicin (Doxil®), and Vorinostat (Suberoylanilide Hydromaxic Acid, Saha, Zolinzatm) in Patients With Relapse/Refractory Multiple Myeloma
Status: Enrolling
Updated: 1/16/2018
Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
Vorinostat, Bortezomib, and Doxorubicin Hydrochloride Liposome in Treating Patients With Relapsed or Refractory Multiple Myeloma
A Phase 1 Dose Escalation Study of Bortezomib (Velcade®), Pegylated Liposomal Doxorubicin (Doxil®), and Vorinostat (Suberoylanilide Hydromaxic Acid, Saha, Zolinzatm) in Patients With Relapse/Refractory Multiple Myeloma
Status: Enrolling
Updated:  1/16/2018
Mount Sinai Hospital
mi
from
New York, NY
Vorinostat, Bortezomib, and Doxorubicin Hydrochloride Liposome in Treating Patients With Relapsed or Refractory Multiple Myeloma
A Phase 1 Dose Escalation Study of Bortezomib (Velcade®), Pegylated Liposomal Doxorubicin (Doxil®), and Vorinostat (Suberoylanilide Hydromaxic Acid, Saha, Zolinzatm) in Patients With Relapse/Refractory Multiple Myeloma
Status: Enrolling
Updated: 1/16/2018
Mount Sinai Hospital
mi
from
New York, NY
Click here to add this to my saved trials
Vorinostat, Bortezomib, and Doxorubicin Hydrochloride Liposome in Treating Patients With Relapsed or Refractory Multiple Myeloma
A Phase 1 Dose Escalation Study of Bortezomib (Velcade®), Pegylated Liposomal Doxorubicin (Doxil®), and Vorinostat (Suberoylanilide Hydromaxic Acid, Saha, Zolinzatm) in Patients With Relapse/Refractory Multiple Myeloma
Status: Enrolling
Updated:  1/16/2018
Duke Comprehensive Cancer Center
mi
from
Durham, NC
Vorinostat, Bortezomib, and Doxorubicin Hydrochloride Liposome in Treating Patients With Relapsed or Refractory Multiple Myeloma
A Phase 1 Dose Escalation Study of Bortezomib (Velcade®), Pegylated Liposomal Doxorubicin (Doxil®), and Vorinostat (Suberoylanilide Hydromaxic Acid, Saha, Zolinzatm) in Patients With Relapse/Refractory Multiple Myeloma
Status: Enrolling
Updated: 1/16/2018
Duke Comprehensive Cancer Center
mi
from
Durham, NC
Click here to add this to my saved trials
Vorinostat, Bortezomib, and Doxorubicin Hydrochloride Liposome in Treating Patients With Relapsed or Refractory Multiple Myeloma
A Phase 1 Dose Escalation Study of Bortezomib (Velcade®), Pegylated Liposomal Doxorubicin (Doxil®), and Vorinostat (Suberoylanilide Hydromaxic Acid, Saha, Zolinzatm) in Patients With Relapse/Refractory Multiple Myeloma
Status: Enrolling
Updated:  1/16/2018
Wake Forest University Comprehensive Cancer Center
mi
from
Winston-Salem, NC
Vorinostat, Bortezomib, and Doxorubicin Hydrochloride Liposome in Treating Patients With Relapsed or Refractory Multiple Myeloma
A Phase 1 Dose Escalation Study of Bortezomib (Velcade®), Pegylated Liposomal Doxorubicin (Doxil®), and Vorinostat (Suberoylanilide Hydromaxic Acid, Saha, Zolinzatm) in Patients With Relapse/Refractory Multiple Myeloma
Status: Enrolling
Updated: 1/16/2018
Wake Forest University Comprehensive Cancer Center
mi
from
Winston-Salem, NC
Click here to add this to my saved trials
A Phase II Trial of Anti-KIR in Smoldering Multiple Myeloma
A Phase II Trial of IPH2101 (Anti-KIR) in Smoldering Multiple Myeloma (SMM)
Status: Enrolling
Updated:  1/16/2018
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
A Phase II Trial of Anti-KIR in Smoldering Multiple Myeloma
A Phase II Trial of IPH2101 (Anti-KIR) in Smoldering Multiple Myeloma (SMM)
Status: Enrolling
Updated: 1/16/2018
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Click here to add this to my saved trials
Safety & Efficacy of Atorvastatin for Prophylaxis of Acute Graft Versus Host Disease in Patients With Hematological Malignancies HLA- Donor Hematopoietic Stem Cell Transplantation
Phase II Trial Evaluating the Safety and Efficacy of Atorvastatin for the Prophylaxis of Acute Graft Versus Host Disease(GVHD) in Patients With Hematological Malignancies Undergoing HLA-Matched Related Donor Hematopoietic Stem Cell Transplantation (HSCT)
Status: Enrolling
Updated:  1/16/2018
Ohio State University
mi
from
Columbus, OH
Safety & Efficacy of Atorvastatin for Prophylaxis of Acute Graft Versus Host Disease in Patients With Hematological Malignancies HLA- Donor Hematopoietic Stem Cell Transplantation
Phase II Trial Evaluating the Safety and Efficacy of Atorvastatin for the Prophylaxis of Acute Graft Versus Host Disease(GVHD) in Patients With Hematological Malignancies Undergoing HLA-Matched Related Donor Hematopoietic Stem Cell Transplantation (HSCT)
Status: Enrolling
Updated: 1/16/2018
Ohio State University
mi
from
Columbus, OH
Click here to add this to my saved trials